FDA Warning Letter to Advance-Esthetic LLC (2026-08-25) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device
Letter issued · posted to fda.gov .
Subject as published: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device
TL;DR
In short: The FDA's Center for Devices and Radiological Health issued a warning letter to Advance-Esthetic LLC (CMS # 729267, August 25, 2026) following an inspection conducted October 27–November 6, 2025, determining that the firm manufactures and markets three devices—Zemits CrystalFrax Pro, Zemits Abigon Pro, and Zemits Bionexis Lite Pro—without required premarket approval or investigational device exemption applications. The FDA found these radiofrequency and light-based devices, marketed for body contouring, cellulite reduction, and collagen stimulation, are adulterated and misbranded because they exceed the scope of the exempt therapeutic massager classification and require either a 510(k) premarket notification or premarket approval application before commercial distribution.
Argus analysis
# FDA Warning Letter Analysis: Advance-Esthetic LLC
**Company and Findings**
Advance-Esthetic LLC, based in Fort Lauderdale, Florida, received a Warning Letter dated August 25, 2026, from the FDA's Center for Devices and Radiological Health. The inspection, conducted October 27–November 6, 2025, identified violations related to three devices: Zemits CrystalFrax Pro, Zemits Abigon Pro, and Zemits Bionexis Lite Pro. These radiofrequency and light-based body contouring devices are marketed without required premarket approval or investigational device exemptions, making them adulterated under federal law.
**Regulatory Citations and Implications**
The violations center on 21 U.S.C. § 351(f)(1)(B) (adulterated device status) and 21 U.S.C. § 352(o) (misbranding), along with implementing regulations 21 CFR 807.81 and 890.5660. The core issue: Advance-Esthetic misclassified its devices as exempt therapeutic massagers under 21 CFR 890.5660, which applies to air pressure-based vibration devices for minor muscle pain. The FDA determined the Zemits products exceed exemption limitations because they use fundamentally different technology (radiofrequency and light-based) and target different intended uses—cellulite reduction, collagen stimulation, and skin rejuvenation—rather than simple muscle pain relief. These distinctions triggered full premarket approval or 510(k) notification requirements.
**Response Timeline and Monitoring Points**
Advance-Esthetic has fifteen business days to submit corrective actions and compliance plans to CDRHEnforcement@fda.hhs.gov. Compliance officers should anticipate a follow-up FDA inspection. The agency warned that failure to resolve violations may trigger seizure, injunction, or civil money penalties. Industry peers should monitor whether Advance-Esthetic pursues PMA submission, seeks 510(k) clearance after device modification, or halts U.S. distribution. Public records of the company's response and any subsequent enforcement actions will provide instructive precedent for device classification disputes in the aesthetic technology sector.
Severity context
Critical severity. Typically reserved for data integrity, sterile-product CGMP, or repeat violations — matters that historically precede injunctions, consent decrees, or import alerts.
Regulatory background
FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
What peer compliance teams typically do next
Most compliance officers at peer companies use a Warning Letter against a named entity as a checklist for their own CAPA program. Common steps: pull the verbatim FDA letter; map each cited 21 CFR section against the team’s SOP library; confirm CAPA coverage; brief the QMR (Quality Management Review) on whether the cited subject matter is in scope for the next internal audit. The 15-business-day response window applies to the cited entity, not to peers — but a documented internal review against the cited subjects is what regulators expect to see if a peer is later inspected on the same topic.
Excerpt from the FDA Warning Letter (public domain, 17 USC §105)
WARNING LETTER Advance-Esthetic LLC MARCS-CMS 729267 — August 25, 2026 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA Electronic Mail Product: Medical Devices Recipient: Recipient Name Kostiantyn Suichmez Recipient Title President and CEO Advance-Esthetic LLC 4101 Ravenswood Rd Ste 110 Fort Lauderdale , FL 33312-5371 United States (b)(6), (b)(7)(C) Issuing Office: Center for Devices and Radiological Health United States WARNING LETTER CMS # 729267 August 25, 2026 Dear Mr. Suichmez: During an inspection of your firm located in Fort Lauderdale, Florida from October 27, 2025, through November 6, 2025, an investigator from the United States Food and Drug Administration (FDA) determined that your firm manufactures and markets Zemits CrystalFrax Pro, Zemits Abigon Pro and Zemits Bionexis Lite Pro. Under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the Act), 21 U.S.C. § 321(h), these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body. Unapproved Device Violations Our inspection revealed that the Zemits CrystalFrax Pro, Zemits Abigon Pro and Zemits Bionexis Lite Pro are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption under section 520(g) of the Act, 21 U.S.C. § 360j(g) for the device as described and marketed. The Zemits CrystalFrax Pro, Zemits Abigon Pro, and Zemits Bionexis Lite Pro are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the device into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k). For a device requiring premarket approval, the notification required by section 510(k) is deemed satisfied when a PMA is pending before the agency [21 CFR 807.81(b)]. The kind of information that your firm needs to submit in order to obtain approval or clearance for the device is described on the Internet at http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/HowtoMarketYourDevice/default.htm. The FDA will evaluate the information that your firm submits and decide whether the product may be legally marketed. Specifically, your firm has listed the Zemits CrystalFrax Pro, Zemits Abigon Pro, and Zemits Bionexis Lite Pro devices under product code ISA, classified under 21 CFR 890.5660. Devices classified under 21 CFR 890.5660 Therapeutic Massagers are electrically powered devices intended for medical purposes, such as to relieve minor muscle aches and pains, and are exempt from premarket notification requirements unless they exceed the limitations at…
Excerpt only. The full verbatim Warning Letter is the source of truth — always read the original before regulatory decisions.
The verbatim FDA Warning Letter is the source of truth. Always read the original before acting on any analysis or summary on this page.
Read the full letter on fda.gov ↗Frequently asked questions
- What is the regulatory background for a Warning Letter warning letter?
- FDA Warning Letters are administratively non-binding but signal that recurring non-compliance may escalate to injunction, seizure, import alert, or Application Integrity Policy invocation.
- What is the standard FDA response window for a warning letter?
- FDA warning letters typically require a written response within 15 working days of receipt, outlining the corrective and preventive actions the company will take.
- Has Advance-Esthetic LLC had FDA enforcement actions before?
- This is the only FDA Warning Letter Argus HQ has on file for Advance-Esthetic LLC as of 2026-09-22. Argus ingests new FDA enforcement records daily.
- What FDA violations was Advance-Esthetic LLC cited for?
- The FDA Warning Letter to Advance-Esthetic LLC (issuing office: Center for Devices and Radiological Health) cites: Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Classification: Warning Letter.
argus.hq
Don’t find out about the next one six weeks late.
Argus reads every FDA Warning Letter the day it publishes, summarizes it against your watchlist, and lands the ones touching your business in your inbox at 6am ET. Plans from $99/month. Cancel any time.
methodology
The analysis above is produced by Anthropic Claude Haiku 4.5 against the verbatim FDA Warning Letter excerpt and is brand-voice lint-checked before publish. The TL;DR is the same summary that ships in the customer email digest. Severity is auto-classified by Argus from the subject string and letter body using rules documented in lib/ingestion/fda-warning-letters.ts.
Argus HQ is informational only. Summaries and analyses are AI-generated and may contain errors, misclassifications, or omissions. Verify against the FDA source URL above. Argus HQ is not a law firm, accounting firm, or regulatory agency, and provides no legal, accounting, financial, medical, or regulatory advice.
Compiled by Argus HQ Research from FDA primary sources · Reviewed by Andy Gaber, Founder
Cite this record
Reusing this data in reporting or research? Here’s a ready-made citation.
Argus HQ Research (2026). FDA Warning Letter to Advance-Esthetic LLC (2026-08-25) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device. Digital Empire Holdings LLC. Retrieved from https://argushq.ai/fda/warning-letter/fda-wl-advance-esthetic-llc-2026-08-25-warning-letter
"FDA Warning Letter to Advance-Esthetic LLC (2026-08-25) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Argus HQ Research, Digital Empire Holdings LLC, 2026, argushq.ai/fda/warning-letter/fda-wl-advance-esthetic-llc-2026-08-25-warning-letter.
Argus HQ Research. "FDA Warning Letter to Advance-Esthetic LLC (2026-08-25) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device." Digital Empire Holdings LLC. Accessed September 27, 2026. https://argushq.ai/fda/warning-letter/fda-wl-advance-esthetic-llc-2026-08-25-warning-letter.
@misc{argushq_argushq_ai_fda_warning_letter_fda_wl_advance_esthetic_llc_2026_08_25_warning_letter_2026,
title = {FDA Warning Letter to Advance-Esthetic LLC (2026-08-25) — Investigational Device Exemptions (IDE)/Premarket Approval Application (PMA) Adulterated Device},
author = {{Argus HQ Research}},
year = {2026},
publisher = {Digital Empire Holdings LLC},
url = {https://argushq.ai/fda/warning-letter/fda-wl-advance-esthetic-llc-2026-08-25-warning-letter},
note = {Accessed: September 27, 2026}
}